Merck broadened the FDA-labeled use of Welireg (belzutifan) by approving it in combination with Eisai’s Lenvima (lenvatinib) for a wider set of kidney cancer patients. The approval covers advanced renal cell carcinoma (RCC) with a clear-cell component and brings a new sequencing option for patients who may be managed with targeted therapy combinations. The updated labeling signals continued confidence in the Welireg–Lenvima strategy, which targets tumor biology through oxygen-sensing and angiogenic pathways. It also reinforces how RCC treatment has shifted toward biomarker- and pathway-driven combinations rather than single-agent targeting. For manufacturers and prescribers, the move affects both competitive positioning in first-line and subsequent-line RCC landscapes and near-term demand forecasting tied to regimen selection.